Clinical Trial Update: Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a dendritic cell vaccine with Imiquimod in malignant glioma has been completed. The study investigates safety and preliminary signals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Dendritic cell vaccine
• Imiquimod (imiquimod)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Malignant Glioma | Phase 1 | Status: COMPLETED